Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study.

Awad, Mark M; Le Bruchec, Yvan; Lu, Brian; Ye, Jason; Miller, Julie Ann; Lizotte, Patrick H; Cavanaugh, Megan E; Rode, Amanda J; Dumitru, Calin Dan; Spira, Alexander

Awad, Mark M; Le Bruchec, Yvan; Lu, Brian; Ye, Jason; Miller, Julie Ann; Lizotte, Patrick H; Cavanaugh, Megan E; Rode, Amanda J; Dumitru, Calin Dan; Spira, Alexander.

Afiliação

Awad MM; Lowe Center for Thoracic Oncology and Dana-Farber Cancer Institute, Boston, MA, United States.
Le Bruchec Y; Bristol Myers Squibb, Princeton, NJ, United States.
Lu B; Bristol Myers Squibb, Princeton, NJ, United States.
Ye J; Acetylon Pharmaceuticals, Inc, Boston, MA, United States.
Miller JA; Bristol Myers Squibb, Princeton, NJ, United States.
Lizotte PH; Dana-Farber Cancer Institute and Belfer Center for Applied Cancer Science, Boston, MA, United States.
Cavanaugh ME; Dana-Farber Cancer Institute and Belfer Center for Applied Cancer Science, Boston, MA, United States.
Rode AJ; Dana-Farber Cancer Institute and Belfer Center for Applied Cancer Science, Boston, MA, United States.
Dumitru CD; Bristol Myers Squibb, Princeton, NJ, United States.
Spira A; Virginia Cancer Specialists (VCS) Research Institute, Fairfax, VA, United States.